BAIN CAPITAL INVESTORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001040508

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltBuy & Hold how tags are computed

Q3 2026 · 8 positions · Total reported value $4.75B · Top-10 concentration 100.0% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 0.0% · 0 new · 0 cut · 0 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q3 2026 13F filing, BAIN CAPITAL INVESTORS LLC disclosed 8 equity positions with a combined reported value of $4.75B. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / Buy & Hold.

The largest disclosed positions as of Q3 2026 were BOBS ($1.32B), AVAH ($1.01B), KMTS ($712.13M). By sector, the heaviest allocations are Health Care 57.1%, Consumer Discretionary 27.9%. Versus the prior quarter, allocation shifted toward Technology (+3.7pp) and away from Consumer Discretionary (-3.6pp).

Versus the prior quarter, BAIN CAPITAL INVESTORS LLC opened 0 new positions, trimmed 0 and fully exited 0, a turnover rate of 0.0% of positions. The portfolio's overlap with the prior quarter was 100% of names.

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

Insider Transactions (Form 4)

Latest BAIN CAPITAL INVESTORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-04-20 Buy Kailera Therapeutics, Inc. 8,398,438 $16.00 SEC filing
2026-04-20 Conversion Kailera Therapeutics, Inc. 17,857,143 — SEC filing

All insider transactions →

Fund Profile

Bain Capital Investors files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 8 positions worth $4.82B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Portfolio Structure

  • 8 positions · $4.82B reported value (Q2 2026)
  • Top 10 holdings = 100.0% of reported value
  • Largest position: BOBS (BOBS DISC FURNITURE INC) at 31.3%
  • Average position size: $601.97M

Sector Tilt

  • Health Care 57.3%
  • Consumer Discretionary 31.4%
  • Information Technology 11.3%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 1 new
  • 7 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund maintained a "Hold" stance across all positions, suggesting a stable, long-term view with no tactical shifts. The increased weights in AVAH, KMTS, NTNX, and WAY indicate selective outperformance or price appreciation in Health Care and Technology, while BOBS and KLRA saw reduced weights. 2. Key moves: No additions or reductions (all actions=Hold). Weight changes were driven purely by price movements (e.g., AVAH +6.78% wt, KLRA -5.70% wt). 3. Portfolio structure: Active management with a tilt toward Health Care (58.85% top-3) and Technology (15.99%), moderate risk appetite via concentrated bets (top-4 = 81.65% of portfolio). 4. Per-holding one-liner: - BOBS: Bobs Discount Furniture (Consumer Discretionary, furniture retail). - AVAH: Amedys Healthcare (Health Care, healthcare services). - KMTS: Kestra Medical Technologies (Health Care, medical devices). - SGRY: Surgery Partners (Health Care, surgical services). - NTNX: Nutanix (Technology, cloud infrastructure). - WAY: Waystar (Technology, healthcare software). - KLRA: Kailera Therapeutics (Health Care, biotech—unverified). - ADV: Advantage Solutions (Consumer Discretionary, marketing services). 5. Style summary: Concentrated, sector-focused fund with no turnover, betting on Health Care/Technology via price appreciation rather than active trades.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 04:03

Sector Allocation

Health Care 57.1%
Technology 15.0%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 95.37M $1.32B 27.80%
27.80%
Hold
2 81.60M $1.01B 21.30%
21.30%
Hold
3 25.17M $712.13M 14.98%
14.98%
Hold
4 49.95M $692.76M 14.57%
14.57%
Hold
5 5.36M $377.07M 7.93%
7.93%
Hold
6 13.24M $335.59M 7.06%
7.06%
Hold
7 26.26M $299.84M 6.31%
6.31%
Hold
8 115.60K $3.00M 0.06%
0.06%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 100% R 100% F1 100% (modelled on 2026-Q2; 8/10 hit)

Historical Backtest (11 quarters)

Avg precision 97% · recall 91% · F1 94% · avg rank error 1.4 · Top-10 turnover 3%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2024-Q1 100% 100% 100% CERE · SGRY · AVAH · ADV CERE · SGRY · AVAH · ADV
2024-Q2 100% 80% 89% CERE · SGRY · AVAH · ADV CERE · SGRY · WAY · AVAH · ADV
2024-Q3 80% 80% 80% CERE · SGRY · WAY · AVAH · ADV SGRY · NTNX · WAY · AVAH · ADV
2024-Q4 100% 100% 100% SGRY · NTNX · WAY · AVAH · ADV SGRY · NTNX · WAY · AVAH · ADV
2025-Q1 100% 83% 91% SGRY · NTNX · WAY · AVAH · ADV SGRY · WAY · NTNX · KMTS · AVAH · ADV
2025-Q2 100% 100% 100% SGRY · WAY · NTNX · KMTS · AVAH · ADV SGRY · WAY · KMTS · AVAH · NTNX · ADV
2025-Q3 100% 100% 100% SGRY · WAY · KMTS · AVAH · NTNX · ADV SGRY · AVAH · KMTS · WAY · NTNX · ADV
2025-Q4 100% 86% 92% SGRY · AVAH · KMTS · WAY · NTNX · ADV COHR · SGRY · KMTS · AVAH · WAY · NTNX · ADV
2026-Q1 86% 86% 86% COHR · SGRY · AVAH · KMTS · WAY · NTNX · ADV BOBS · SGRY · AVAH · KMTS · WAY · NTNX · ADV
2026-Q2 100% 88% 93% BOBS · SGRY · AVAH · KMTS · WAY · NTNX · ADV BOBS · SGRY · AVAH · KMTS · KLRA · NTNX · WAY · ADV
2026-Q3 ★ 100% 100% 100% BOBS · SGRY · AVAH · KMTS · KLRA · NTNX · WAY · ADV BOBS · AVAH · KMTS · SGRY · NTNX · WAY · KLRA · ADV

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did BAIN CAPITAL INVESTORS LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, BAIN CAPITAL INVESTORS LLC reported 8 equity positions worth $4.75B in aggregate; its largest disclosed positions were BOBS ($1.32B), AVAH ($1.01B), KMTS ($712.13M).

How large is BAIN CAPITAL INVESTORS LLC's portfolio?

BAIN CAPITAL INVESTORS LLC reported $4.75B of long equity holdings across 8 positions as of 2026-Q3. Top-10 holdings account for 100.0% of reported value.

What is BAIN CAPITAL INVESTORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / Buy & Hold, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/bain-capital-investors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →